PDCD1 and leukemia: For example, PD-1 and CTLA-4 blockade was recently shown to prevent the deletion of tumor-reactive T cells, whereas additional blockade of LAG-3 was vital to promote greater effector function among these persisting TIL – providing a clear survival benefit for leukemia-bearing hosts [47].